In Vivo CAR-T Therapy: From Concept to Clinical Momentum

CAR-T cell therapy has transformed the treatment landscape for hematological cancers, yet its widespread adoption remains limited by the complexity of ex vivo manufacturing. Patient-specific cell collection, genetic modification, and reinfusion introduce high costs, long timelines, and scalability challenges.

To address these barriers, in vivo CAR-T has emerged as a new strategy—engineering T cells directly inside the patient using nucleic acid delivery systems. This approach has gained rapid attention across academia, biotech, and big pharma.

Clinical Progress Preceding Academic Validation
Interestingly, clinical development in in vivo CAR-T advanced before large-scale academic confirmation was published.

In June 2025, Capstan Therapeutics announced the initiation of a Phase I clinical trial for CPTX2309, an in vivo CAR-T candidate targeting B-cell–mediated autoimmune diseases. The therapy uses targeted lipid nanoparticles (tLNPs) to deliver CAR-encoding mRNA directly to immune cells.

This announcement marked one of the first clinical applications of in vivo CAR-T technology.

Science Reinforces the Strategy
Later the same month, a landmark study published in Science provided strong preclinical evidence supporting the in vivo CAR-T concept. The research demonstrated:

Efficient in vivo generation of CAR-T cells
Targeted delivery using ligand-modified lipid nanoparticles
Effective B-cell depletion
Favorable tolerability in murine and non-human primate models
The results aligned closely with early clinical hypotheses, reinforcing confidence in in vivo genetic programming approaches.

Industry Validation at the Platform Level
Momentum accelerated further when AbbVie acquired Capstan Therapeutics in an all-cash transaction valued at $2.1 billion. The acquisition highlighted growing industry confidence in:

In vivo immune cell engineering
mRNA-based therapeutic platforms
Advanced lipid nanoparticle delivery systems
Rather than focusing on a single asset, the deal underscored the strategic value of the delivery platform itself.

Delivery Systems as the Key Enabler
At the core of in vivo CAR-T development is lipid nanoparticle design. Unlike vaccines, these systems must achieve:

Precise cell targeting
Controlled circulation time
Efficient intracellular delivery
Reproducible manufacturing
This has shifted attention toward excipients and functional materials that enable consistency and tunability.

Functional PEG-Lipids in Targeted LNP Design
Phospholipid–PEG conjugates are widely used in LNP formulations to improve colloidal stability and reduce nonspecific interactions.

In targeted systems, functional PEG-lipids also serve as chemical anchors for ligands, antibodies, or peptides. Among these, DSPE-PEG-Maleimide is commonly used to conjugate thiol-modified targeting moieties through well-controlled chemistry, making it a practical choice for cell-specific delivery strategies.

Supporting In Vivo CAR-T and mRNA Delivery Research
To support advanced mRNA and in vivo CAR-T delivery research, Biopharma PEG provides a portfolio of functional PEG-lipids used in LNP formulation and surface modification, including:

mPEG-DSPE (MW 1K–20K)
DSPE-PEG-NH₂ (MW 1K–20K)
DSPE-PEG-MAL (MW 1K–20K)
DSPE-PEG-Mannose (MW 1K–20K)
DSPE-PEG-SC (MW 1K–20K)
DSPE-PEG-c(RGDyK) (MW 2K, 3.4K, 5K, 10K, 20K)
These materials are supplied to support early research, formulation optimization, and translational development in next-generation mRNA and cell therapy programs.

Outlook
In vivo CAR-T remains an emerging modality, but recent clinical progress, academic validation, and major pharmaceutical investment suggest strong long-term potential. As delivery technologies mature, the integration of mRNA engineering, targeted lipid nanoparticles, and functional PEG-lipids is expected to play a defining role in expanding the reach of cell therapy.